Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: Results from a randomised controlled trial

Salvatore Siena, Josep Tabernero, Gyorgy Bodoky, David Cunningham, Fernando Rivera, Paul Ruff, Jean Luc Canon, Reija Koukakis, Gaston Demonty, Guy Hechmati, Jean Yves Douillard

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


© Published by the BMJ Publishing Group Limited. Introduction Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. Methods A randomised phase 3 open-label study of first-line panitumumab+FOLFOX4 vs FOLFOX4 enrolled adults with untreated metastatic colorectal cancer and an Eastern Cooperative Oncology Group performance status of 0-2. This analysis includes patients with wild-type RAS tumours (n=505). Quality of life (prespecified end point) was assessed using the EuroQoL 5-domain health state index and overall health rating in all patients and by early tumour shrinkage status (≥30% reduction in size by week 8; exploratory end point). Differences in quality of life were assessed using analysis of covariance and a mixed-effect piecewise linear model, and were also analysed by skin toxicity severity. Results There were no statistically significant differences between treatment arms from baseline to progression or to discontinuation. Grade 3+ skin toxicity was reported by 38% of patients receiving panitumumab+FOLFOX4 and 2% receiving FOLFOX4 alone. There were no significant differences in quality of life between patients with grade 0-2 skin toxicity and those with grade 3+ skin toxicity. More patients receiving panitumumab+FOLFOX4 vs FOLFOX4 had early tumour shrinkage (p<.001). In patients with tumour symptoms at baseline, there were statistically significant improvements in quality of life in those with early tumour shrinkage versus those without early tumour shrinkage. Conclusions Addition of panitumumab to FOLFOX4 in first-line therapy for metastatic colorectal cancer prolongs survival and has no negative effect on overall quality of life compared with FOLFOX4 alone. Specific quality of life assessments for skin toxicity should be included in study designs to better define the direct effect of these adverse events. Trial registration number NCT00364013.
Original languageEnglish
Article numbere000041
JournalESMO Open
Issue number2
Publication statusPublished - 1 Mar 2016


  • EGFR inhibitors
  • chemotherapy
  • metastatic colorectal cancer
  • quality of life
  • tumour shrinkage


Dive into the research topics of 'Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: Results from a randomised controlled trial'. Together they form a unique fingerprint.

Cite this